Healthcare
Zydus Therapeutics’ Saroglitazar NDA for Primary Biliary Cholangitis Receives Priority Review from US FDA
Zydus Therapeutics has received Priority Review from the US FDA for its New Drug Application for saroglitazar in Primary Biliary Cholangitis, with a PDUFA target action date of November 27, 2026.